September 7, 2017 / 9:02 PM / 10 months ago

BRIEF-Amgen says Aimovig reduces monthly migraines in patients who failed preventive therapies​

Sept 8 (Reuters) - Amgen Inc

* Amgen Inc says ‍new data demonstrate Aimovig (erenumab) reduced monthly migraine days in patients who failed previous preventive therapies​

* Amgen Inc says ‍additionally, results from a dedicated study in patients with stable angina adds further support to safety profile of aimovig​

* Says ‍safety profile of Aimovig was similar to placebo across both treatment arms in phase 2 study​

* Says ‍no adverse event was reported in greater than five percent of patients treated with Aimovig​

* Says ‍most common adverse events were injection site pain, upper respiratory tract infection and nausea​

* Amgen Inc - ‍study met its primary endpoint of noninferiority, showing no difference in exercise time among participants receiving Aimovig or placebo​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below